Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer—retrospective analysis of response

BACKGROUND: Given the tolerability of nPG in first-line therapy, we desired to evaluate the response and toxicity profiles of second-line gemcitabine with nab-paclitaxel (nPG) following FOLFIRINOX. METHODS: We retrospectively identified 30 patients who received first-line FOLFIRINOX for unresectable...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastrointest Oncol
Asıl Yazarlar: Nguyen, Khanh T., Kalyan, Aparna, Beasley, H. Scott, Singhi, Aatur D., Sun, Weijing, Zeh, Herbert J., Normolle, Daniel, Bahary, Nathan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5506273/
https://ncbi.nlm.nih.gov/pubmed/28736642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.01.23
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller